Inactief instrument

Andere talen Compugen Ltd. Deutsche Boerse AG

Aandelen

CW9

IL0010852080

Geschatte realtime Tradegate Andere beurzen 16:26:50 17-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,705 ^EUR	-66,24%		-9,82%	0,00%

27/06	Transcript : Compugen Ltd. - Special Call
30/05	Compugen Ltd. ontvangt mijlpaalbetaling van Astrazeneca na dosering van de eerste patiënt in de tweede Fase 3 studie die Rilvegostomig evalueert	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Compugen to Present at Upcoming Antibody Industrial Symposium	17/06
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	30/05
Compugen Ltd. to Receive Milestone Payment from Astrazeneca Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	30/05
Compugen : Reports First Quarter 2024 Results	20/05
Earnings Flash (CGEN) COMPUGEN Reports Q1 Revenue $2.6M, vs. Street Est of $1.2M	20/05
Compugen: Q1 Earnings Snapshot	20/05
Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	20/05
Compugen Reports First Quarter 2024 Results	20/05
Compugen : Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential	16/05
Compugen Names David Silberman CFO	15/05
Compugen Appoints David Silberman as Chief Financial Officer	15/05
Compugen Ltd. Announces CFO Changes, Effective August 15, 2024	15/05
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024	06/05
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	26/04
Compugen : To Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	25/04
Compugen to Participate in Two Upcoming Investor Conferences	03/04
Compugen : Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	11/03
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	11/03
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024	07/03
Compugen : To Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024	06/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Compugen Ltd. Deutsche Boerse AG

Aandelen

CW9

IL0010852080

Andere talen

Filters